Mucosal vaccines: The promise and the challenge

Nature Reviews Immunology

Volumn 6, Issue 2, 2006, Pages 148-158

  Neutra, Marian R ^a,b   Kozlowski, Pamela A ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIAL VACCINE; CHITOSAN; CHOLERA TOXIN; CYTOKINE; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; FLAGELLIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LIPOSOME; LIVE VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GP 120; OLIGONUCLEOTIDE; PEPTIDE VACCINE; POLIOMYELITIS VACCINE; PORIN; PROTEASOME; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TOXIN; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VACCINIA VACCINE; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTATION; ADENOVIRUS VECTOR; CELLULAR IMMUNITY; CLINICAL TRIAL; DIARRHEA; DRUG CAPSULE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG UPTAKE; ENTERIC COATED TABLET; ENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; MUCOSA INFLAMMATION; MUCOSAL IMMUNITY; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL GENE DELIVERY SYSTEM; VIREMIA; VIRUS INFECTION; VIRUS VECTOR;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; VACCINES;

EID: 33644836224     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1777     Document Type: Review

References (123)

1. Levine, M. M. Immunization against bacterial diseases of the intestine. J. Pediatr. Gastroenterol. Nutr. 31, 336-355 (2000).
2. Lamm, M. E. Interactions of antigens and antibodies at mucosal surfaces. Annu. Rev. Microbiol. 51, 311-340 (1997).
3. Modlin, J. F. Poliomyelitis in the United States: the final chapter? JAMA 292, 1749-1751 (2004).
4. Kapikian A. Z. et al. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J. Infect. Dis. 174, S65-S72 (1996).
5. Belshe, R. B. et al. The efficacy of live attenuated, cold-adapted, trivalent intranasal influenza virus vaccine in children. N. Engl. J. Med. 338, 1405-1412 (1998).
6. Kozlowski, P. A. & Neutra, M. R. The role of mucosal immunity in prevention of HIV transmission. Curr. Mol. Med. 3, 217-228 (2003).
7. Belyakov, I. M. & Berzofsky, J. A. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20, 247-253 (2004).
8. Neutra, M. R. & Kraehenbuhl J. P. in Mucosal Immunology 3rd edn (eds Ogra, P. L. et al.) 111-130 (Academic Press, San Diego, 2005).
9. Brandtzaeg, P. et al. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol. Today 20, 141-151 (1999).
10. van Egmond, M. et al. IgA and the IgA Fc receptor. Trends Immunol. 22, 205-211 (2001).
11. Kagnoff, M. F. & Eckmann, L. Epithelial cells as sensors for microbial infection. J. Clin. Invest. 100, S51-S55 (1997).
12. Izadpanah, A., Dwinell, M. B., Eckmann, L., Varki, N. M. & Kagnoff, M. F. Regulated MIP-3α/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. Am. J. Physiol. Gastroint. Liver Physiol. 280, G710-G719 (2001). One of a series of studies by this group, documenting the signals produced by epithelial cells in response to microorganisms and their products.
13. MacDonald, T. T. & Monteleone, G. Immunity, inflammation and allergy in the gut. Science 307, 1920-1925 (2005). A timely review of the basic cellular mechanisms underlying common gastrointestinal diseases that are associated with dysfunction of the mucosal immune system.
14. Rakoff-Nahoum, S., Pagliano, J., Esalmi-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 118, 229-241 (2004). Recent evidence that TLR-mediated responses to non-pathogenic bacteria in the gut prevent local inflammation and are required for maintenance of a healthy epithelial barrier.
15. Backhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A. & Gordon, J. I. Host-bacterial mutualism in the human intestine. Science 307, 1915-1920 (2005). A fascinating overview of our long and intimate symbiotic relationship with commensal intestinal bacteria.
16. Kozlowski, P. A., Cu-Uvin, S., Neutra, M. R. & Flanigan, T. P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun. 65, 1387-1394 (1997).
17. Kozlowski, P. A. et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. 169, 566-574 (2002). A detailed description of methods for analysis of antibodies in human secretions, and the influence of vaccination site on local antibody production.
18. Mestecky, J., Moro, I., Kerr, M. A. & Woof, J. M. in Mucosal Immunology, 3rd edn (eds Ogra, P. L. et al.) 153-182 (Academic Press, San Diego, 2005).
19. Kaetzel, C. S., Robinson, J. K., Chintalacharuvu, K. R., Vaerman, J. P. & Lamm, M. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc. Natl Acad. Sci. USA 88, 8796-8800 (1991).
20. Hutchings, A. B., Helander, A., Silvey, K. J., Lucas, W. T. & Neutra, M. R. Secretory IgA antibodies against the σ1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. J. Virol. 78, 947-957 (2004).
21. Robinson, J. K., Blanchard, T. G., Levine, A. D., Emancipator, S. N. & Lamm, M. E. A mucosal IgA-mediated excretory immune system in vivo. J. Immunol. 166, 3688-3692 (2001).
22. Black, K. P., Cummins, J. E. & Jackson, S. Serum and secretory IgA from HIV-infected individuals mediate antibody-dependent cellular cytotoxicity. Clin. Immunol. Immunopathol. 81, 182-190 (1996).
23. Eriksson, K. et al. Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect. Immun. 66, 5889-5896 (1998).
24. Kutteh, W. H., Mestecky, J. & Wira, C. R. in Mucosal Immunology, 3rd edn (eds Ogra, P. L. et al.) 1631-1646 (Academic Press, San Diego, 2005).
25. Parr, E. L. & Parr, M. B. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J. Virol. 71, 8109-8115 (1997).
26. Kozlowski, P. A. et al. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J. Acquir. Imm. Defic. Syndr. 24, 297-309 (2000).
27. Yoshida, M. et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20, 769-783 (2004).
28. Mantis, N. J. et al. Selective adherence of immunoglobulin A to murine Peyer's patch M Cells: evidence for a novel IgA receptor. J. Immunol. 169, 1844-1851 (2002).
29. Corthesy, B. et al. A pathogen-specific epitope inserted into recombinant secretory immunoglobulin is immunogenic by the oral route. J. Biol. Chem. 52, 33670-33677 (1996).
30. + cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102, 2072-2081 (1998).
31. Veazey, R. S. & Lackner, A. A. Getting to the guts of HIV pathogenesis. J. Exp. Med. 200, 697-700 (2004). A review of the predilection of HIV and SIV for the intestinal mucosa and implications for pathogenesis and vaccines.
32. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200, 749-759 (2004).
33. O'Leary, A. D. & Sweeney, E. C. Lymphoglandular complexes of the colon: structure and distribution. Histopathology 10, 267-283 (1986).
34. Neutra, M. R., Mantis, N. J. & Kraehenbuhl, J.-P. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nature Immunol. 2, 1004-1009 (2001).
35. Cook, D. N. et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 12, 495-503 (2000).
36. Iwasaki, A. & Kelsall, B. L. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3α, MIP-3β, and secondary lymphoid organ chemokine. J. Exp. Med. 191, 1381-1394 (2000). An excellent analysis of the DCs of Peyer's patches, and their functions in the specialized microcompartments within organized mucosal lymphoid tissues.
37. + dendritic cells. J. Immunol. 171, 2797-2803 (2003).
38. Hopkins, S. A., Niedergang, F., Corthesy-Theulaz, I. E. & Kraehenbuhl, J. P. A recombinant Salmonella typhimurium vaccine strain is taken up and survives within murine Peyer's patch dendritic cells. Cell. Microbiol. 2, 59-68 (2000).
39. Shreedhar, V. K., Kellsall, B. L. & Neutra, M. R. Cholera toxin induces migration of dendritic cells from the sub-epithelial dome region to T and B cell areas of Peyer's patches. Infect. Immun. 71, 504-509 (2003).
40. +, and double negative Peyer's patch dendritic cells. J. Immunol. 166, 4884-4890 (2001).
41. MacPherson, G. G. & Liu, L. M. Dendritic cells and Langerhans cells in the uptake of mucosal antigens. Curr. Top. Microbiol. Immunol. 236, 33-53 (1999).
42. Holt, P. G., Schon-Hegrad, M. A. & McMenamin, P. G. Dendritic cells in the respiratory tract. Int. Rev. Immunol. 6, 139-149 (1990).
43. Miller, C. J., McChesney, M. & Moore, P. F. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab. Invest 67, 628-634 (1992).
44. Niess, J. H. et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307, 254-258 (2005). Identification of a novel mechanism for migration of DCs into the intestinal epithelium.
45. Fagarasan, S. & Honjo, T. Intestinal IgA synthesis: regulation of front-line body defences. Nature Rev. Immunol. 3, 63-72 (2003). Evidence for a mechanism whereby local IgA production can be rapidly increased during a mucosal memory response.
46. Mayer, L. & Shao L. Therapeutic potential of oral tolerance. Nature Rev. Immunol. 4, 407-419 (2004).
47. Belyakov, I. M., Hammond, S. A., Ahlers, J. D., Glenn, G. M. & Berzofsky, J. A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest 113, 998-1007 (2004). Some nice detective work explaining how immunization through the skin can result in mucosal immune responses.
48. Kunkel, E. J. & Butcher, E. C. Plasma-cell homing. Nature Rev. Immunol. 3, 822-829 (2003).
49. Mora, J. R. et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424, 88-93 (2003).
50. Mestecky, J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7, 265-276 (1987).
51. Hieshima, K. et al. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J. Immunol. 173, 3668-3675 (2004).
52. Lindholm, C., Naylor, A., Johansson, E. L. Quiding-Jarbrink, M. Mucosal vaccination increases endothelial expression of mucosal addressin cell adhesion molecule 1 in the human gastrointestinal tract. Infect. Immun. 7, 1004-1009 (2004).
53. 7 integrin. Eur. J. Immunol. 32, 1445-1454 (2002).
54. H1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J. Exp. Med. 198, 369-377 (2003).
55. + T cell population in different tissues. Vaccine 22, 1390-1394 (2004).
56. Staats, H. F., Montgomery, S. P. & Palker, T. J. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses 13, 945-952 (1997).
57. H2 help for virus-specific immune responses in reproductive tissues. J. Immunol. 161, 5952-5958 (1998).
58. Rudin, A., Riise, G. & Holmgren, J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect. Immun. 67, 2884-2890 (1999).
59. Gallichan, W. S. & Rosenthal, K. L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177, 1155-1161 (1998).
60. Egan, M. A. et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res. Hum. Retroviruses 20, 989-1004 (2004).
61. Enose, Y. et al. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 298, 306-316 (2002).
62. Belyakov, I. M. et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl Acad. Sci. USA. 95, 1709-1714 (1998).
63. Ryan, E. J., Daly, L. M. & Mills, H. G. Immunoregulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol. 19, 293-304 (2001). A review of mucosal adjuvants and strategies to increase the uptake of antigens into mucosal tissues.
64. Jones, B. D., Ghori, N. & Falkow, S. Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J. Exp. Med. 180, 15-23 (1994).
65. Sicinski, P. et al. Poliovirus type 1 enters the human host through intestinal M cells. Gastroenterology 98, 56-58 (1990).
66. Seong, S. Y., Cho, N. H., Kwon, I. C. & Jeong, S. Y. Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect. Immun. 67, 3587-3592 (1999).
67. Baca-Estrada, M. E., Foldvari, M., Babiuk, S. L. & Babiuk, L. A. Vaccine delivery: lipid-based delivery systems. J. Biotechnol. 83, 91-104 (2000).
68. Chabot, S. et al. A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 23, 1374-1383 (2005).
69. H2 responses following nasal delivery. Vaccine 19, 1188-1198 (2000).
70. Frey, A. et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J. Exp. Med. 184, 1045-1060 (1996).
71. Mantis, N. J., Frey, A. & Neutra, M. R. Accessibility of glycolipid and oligosaccharide epitopes on rabbit villus and follicle-associated epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G915-G923 (2000).
72. Choi, W. S., Pal-Ghosh, R. & Morrow, C. D. Expression of human immunodeficiency virus type 1 (HIV-1) gag, pol, and env proteins from chimeric HIV-1-poliovirus minireplicons. J. Virol. 65, 2875-2883 (1991).
73. Tacket, C. O., Sztein, M. B., Losonsky, G. A., Wasserman, S. S. & Estes, M. K. Humoral, mucosal, and cellular responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108, 241-247 (2003).
74. Haneberg, B., Herland Berstad, A. K. & Holst, J. Bacteria-derived particles as adjuvants for non-replicating nasal vaccines. Adv. Drug Deliv. Rev. 51, 143-147 (2001).
75. Elson, C. O. & Dertzbaugh, M. T. Mucosal adjuvants, in Mucosal Immunology 3rd Edn. (eds Ogra, R. et al.) 967-986 (Academic Press, New York, 2005).
76. van Ginkel, F. W., Jackson, R. J., Yuki, Y. & McGhee, J. R. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778-4782 (2000).
77. Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004).
78. Lycke, N. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunol. Lett. 97, 193-198 (2005). A review of the promise and problems of bacterial enterotoxins as mucosal adjuvants, and description of a new approach.
79. Belyakov, I. M., Ahlers, J. D., Clements, J. D., Strober, W. & Berzofsky, J. A. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J. Immunol. 165, 6454-6462 (2000).
80. Gallichan, W. S. et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166, 3451-3457 (2001).
81. + T cells in vivo. J. Immunol. 169, 3914-3919 (2002).
82. Malkevitch, N. & Robert-Guroff, M. A call for replicating vector prime-boost strategies in HIV vaccine design. Expert Rev. Vaccines 4, S105-S117 (2004). An extensive review of studies using live and non-living viral and bacterial vectors, and various systemic and mucosal vaccine strategies, to induce anti-HIV immune responses in monkeys.
83. Lemiale, F. et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77, 10078-10087 (2003).
84. Milman, G. & Sharma, O. Mechanisms of HIV/SIV mucosal transmission. AIDS Res. Human Retroviruses 10, 1305-1312 (1994).
85. Amerongen, H. M. et al. Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J. Acquir. Immune Defic. Syndr. 4, 760-765 (1991).
86. Hu, J., Gardner, M. B. & Miller, C. J. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74, 6087-6095 (2000).
87. Fujimura, Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch. 436, 560-566 (2000).
88. Spira, A. I. et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183, 215-225 (1996).
89. + T cells. Science 286, 1353-1357 (1999).
90. Mazzoli, S. et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nature Med. 3, 1250-1257 (1997).
91. Kaul R. et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol. Lett. 79, 3-13 (2001).
92. Belyakov, I. M. et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nature Med. 7, 1320-1326 (2001).
93. Mäkitalo, B. et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J. Gen. Virol. 85, 2407-2419 (2004).
94. Bertley, F. M. N. et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus ankara nasal vaccination in nonhuman primates. J. Immunol. 172, 3745-3757 (2004).
95. Fuller, D. H. et al. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J. Virol. 76, 3309-3317 (2002).
96. Nilsson, C. et al. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12, 2261-2270 (1998).
97. Tenner-Racz, K. et al. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc. Natl Acad. Sci. USA 101, 3017-3022 (2004).
98. +T lymphocytes by attenuated simian immunodeficiency virus. J. Virol. 74, 8762-8766 (2000).
99. Crotty, S. et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J. Virol. 75, 7435-7452 (2001). This paper reports the exploitation of a viral vector that naturally invades organized mucosal lymphoid tissues to deliver SIV genes and induce partial protection against subsequent mucosal challenge.
100. Burton, D. R. Antibodies, viruses, and vaccines. Nature Rev. Immunol. 2, 706-713 (2002). A thorough discussion of the potential importance of antibodies and their mechanisms of action in prevention and control of HIV.
101. Parren, P. W. H. I. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
102. Veazey, R. S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature Med. 9, 1-4 (2003).
103. Fotopoulos, G. et al. Transepithelial transport of HIV-1 by M cells is receptor mediated. Proc. Natl Acad. Sci. USA 99, 9410-9414 (2002).
104. Janoff, E. N. & Smith, P. D. Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis and management. Gastroenterology 120, 607-621 (2001).
105. Fantini, J. et al. Synthetic and soluble analogues of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry. J. Biol. Chem. 272, 7245-7252 (1997).
106. Alfsen, A. & Bomsel, M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J. Biol. Chem. 277, 25649-25659 (2002).
107. Bomsel, M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nature Med. 3, 42-47 (1997).
108. Alfsen, A., Iniguez, P., Bouguyon, E. & Bomsel, M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 166, 6257-6265 (2001).
109. Hocini, H. et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to gp160. AIDS Res. Hum. Retroviruses 13, 1179-1185 (1997).
110. Matoba, N. et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking antibodies. Proc. Natl Acad. Sci. USA 101, 13584-13589 (2004).
111. Clerici, M. et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41. AIDS 16, 1731-1741 (2002).
112. Wright, P. F. et al. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J. Infect. Dis. 189, 1221-1231 (2004).
113. McDermott, A. B. et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J. Virol. 78, 3140-3144 (2004).
114. Wassén, L., Schön, K., Holmgren, J., Jertborn, M. & Lycke, N. Local intravaginal vaccination of the female genital tract. Scand. J. Immunol. 44, 408-414 (1996).
115. Rudin, A., Johansson, E.-L., Bergquist, C. & Holmgren, J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun. 66, 3390-3396 (1998).
116. Quiding, M. et al. Intestinal immune responses in humans: oral cholera vaccination induces strong intestinal antibody responses and interferon-γ production and evokes immunological memory. J. Clin. Invest 88, 143-148 (1991).
117. Kantele, A. et al. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect. Immun. 66, 5630-5635 (1998).
118. Forrest, B. D., Shearman, D. J. C. & LaBrooy, J. T. Specific immune responses in humans following delivery of live typhoid vaccine. Vaccine 8, 209-212 (1990).
119. Ogra, P. L. & Karzon, D. T. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J. Immunol. 102, 1423-1430 (1969).
120. Ogra, P. L. & Ogra, S. S. Local antibody response to poliovaccine in the human female genital tract. J. Immunol. 110, 1307-1311 (1973).
121. gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. J. Immunol. 158, 5321-5329 (1997).
122. Vajdy, M. et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res. Hum. Retroviruses 20, 1269-1281 (2004).
123. Wang, S.-W. et al. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. J. Virol. 74, 10514-10522 (2000).